MG53 regulates the ubiquitination and degradation of RAC1, a small GTPase with oncogenic function, this effect, in turn, inhibits the malignant progression of hepatocellular carcinoma and improves the resistance of hepatocellular carcinoma to sorafenib treatment by blocking the RAC1/MAPK signaling pathway (17). This evidence concerns the gene TRIM72 and hepatocellular carcinoma.